Pemetrexed as first-line therapy for non-squamous non-small cell lung cancer

Pemetrexed is a new cytotoxic agent that is a standard of care for the second-line treatment of non-small cell lung cancer (NSCLC) and in combination with cisplatin in treatment of malignat pleural mesothelioma. It has been studied in numerous phase II and III trials in combination with different dr...

Full description

Saved in:
Bibliographic Details
Published in:Therapeutics and clinical risk management 2009, Vol.5 (default), p.781-787
Main Authors: Ricciardi, Serena, Tomao, Silverio, de Marinis, Filippo
Format: Article
Language:English
Subjects:
first-line setting
Lung cancer
non-small cell lung cancer
non-squamous carcinoma
pemetrexed
Review
Citations: Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Pemetrexed is a new cytotoxic agent that is a standard of care for the second-line treatment of non-small cell lung cancer (NSCLC) and in combination with cisplatin in treatment of malignat pleural mesothelioma. It has been studied in numerous phase II and III trials in combination with different drugs or as single agent. Recently, pemetrexed has been approved in combination with cisplatin for the first-line treatment of patients with locally advanced or metastatic NSCLC other than squamous cell histology. The toxicity is acceptable and similar to that of other NSCLC regimens. The postinduction maintenance therapy with pemetrexed is being evaluated in a phase III, double-blind, placebo-controlled study.
ISSN:1176-6336
1178-203X
1178-203X
DOI:10.2147/tcrm.s3195